Question 1

What is Ara-290?

Accepted Answer

It is an 11-amino-acid peptide (INN cibinetide; also pHBSP) derived from the helix-B region of erythropoietin and engineered to be non-erythropoietic. On this workspace it is handled as a Research Use Only material.

Question 2

How does it differ from erythropoietin (EPO)?

Accepted Answer

Research describes Ara-290 as designed to activate the innate repair receptor (an EPO-receptor / β-common-receptor complex) without driving red-blood-cell production, distinguishing it from EPO, which signals through the EPO-receptor homodimer. This is a mechanistic research distinction, not a clinical claim.

Question 3

How is it thought to act in research models?

Accepted Answer

It is studied as a selective ligand of the innate repair receptor, a pathway associated in the literature with tissue-protective and innate-immune-modulating signaling. This mechanism has been characterized largely in vitro and in animal models.

Question 4

What is the current research status?

Accepted Answer

The evidence base is predominantly preclinical, with a small number of early-phase (Phase 2) human trials, mainly in sarcoidosis-associated small-fiber neuropathy. It is investigational and the human data are limited and early-stage.

Question 5

Is it approved by regulators?

Accepted Answer

It is not approved by the FDA or other major regulators for clinical use and remains an investigational compound; on this workspace it is a research-use-only material. This is regulatory information, not medical advice.

Question 6

What dosing is used in research?

Accepted Answer

Research-reported ranges vary across the available studies. This workspace does not provide dosing guidance; consult the linked protocol reference for documented research ranges. This is not medical advice.

Question 7

How is it typically handled and stored in a research setting?

Accepted Answer

It is generally supplied as a lyophilized powder and reconstituted with sterile or bacteriostatic water for research handling; lyophilized peptide is commonly stored frozen and protected from light, with reconstituted material refrigerated and used within a limited window per supplier documentation. Note that its very short plasma half-life is a frequently studied property. This is general handling information only, not medical guidance.

Phase	Daily reference amount	Units / volume
Week 1	2 mg (2,000 mcg)	25 units (0.25 mL)
Weeks 2–8 (or up to 16)	4 mg (4,000 mcg)	50 units (0.50 mL)

Ara-290.

Calculated volume reference

Cited protocol & reconstitution guide